Показать сокращенную информацию
dc.contributor.author | Ahmadi P. | |
dc.contributor.author | Muguruma K. | |
dc.contributor.author | Chang T.C. | |
dc.contributor.author | Tamura S. | |
dc.contributor.author | Tsubokura K. | |
dc.contributor.author | Egawa Y. | |
dc.contributor.author | Suzuki T. | |
dc.contributor.author | Dohmae N. | |
dc.contributor.author | Nakao Y. | |
dc.contributor.author | Tanaka K. | |
dc.date.accessioned | 2022-02-09T20:46:43Z | |
dc.date.available | 2022-02-09T20:46:43Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2041-6520 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/170218 | |
dc.description.abstract | Selective cell tagging (SeCT) therapy is a strategy for labeling a targeted cell with certain chemical moietiesviaa catalytic chemical transformation in order to elicit a therapeutic effect. Herein, we report a cancer therapy based on targeted cell surface tagging with proapoptotic peptides (Ac-GGKLFG-X; X = reactive group) that induce apoptosis when attached to the cell surface. Using either Au-catalyzed amidation or Ru-catalyzed alkylation, these proapoptotic peptides showed excellent therapeutic effects bothin vitroandin vivo. In particular, co-treatment with proapoptotic peptide and the carrier-Ru complex significantly and synergistically inhibited tumor growth and prolonged survival rate of tumor-bearing mice after only a single injection. This is the first report of Ru catalyst applicationin vivo, and this approach could be used in SeCT for cancer therapy. | |
dc.relation.ispartofseries | Chemical Science | |
dc.title | In vivometal-catalyzed SeCT therapy by a proapoptotic peptide | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 37 | |
dc.relation.ispartofseries-volume | 12 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 12266 | |
dc.source.id | SCOPUS20416520-2021-12-37-SID85116416695 |